3Halford JC.Obesity drugs in clinical development[J].Curr Opin Investig Drugs,2006,7(4):312-318.
4Kirkham TC.Endocannabinoi ds in the regulation of appetite and body weight[J].Behav Pharmacol,2005,16(5-6):297-313.
5Arena Pharmaceuticals Inc.Arena Pharmaceuticals announces initiation of phase 2b clinical trial of its novel anyi-obesity compound[N].Press Release,2005-06-23.
6Defronzo R,Ratner R,Han J,et al.Effects of exenatide(synthetic exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes[C ].Program and abstracts of the 64 th Scientific Sessions of the American Diabetes Association.2004.
7Curren Mp,Scott LJ.Orlistat:a review of its use in the management of patients with obesity[J].Drugs,2004,64(24):2845-2864.
8Heffernan M,Summers RJ,Thorburn A,et al.The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolisn following chronic treatment in obese mice and β3-AR knock-out mece[ J ].Endocrinology,2001,142 (12):5182-5189.
9Hu B,Jennings LL.Orlly bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type 2diabetes mellitus[J].Prog Med Chem,2003,41:167-194.
